JP2019513738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513738A5 JP2019513738A5 JP2018552675A JP2018552675A JP2019513738A5 JP 2019513738 A5 JP2019513738 A5 JP 2019513738A5 JP 2018552675 A JP2018552675 A JP 2018552675A JP 2018552675 A JP2018552675 A JP 2018552675A JP 2019513738 A5 JP2019513738 A5 JP 2019513738A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- compound
- activity
- pkr2
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040125 Prokineticin-2 Human genes 0.000 claims description 128
- 101710103829 Prokineticin-2 Proteins 0.000 claims description 128
- 102000004136 Vasopressin Receptors Human genes 0.000 claims description 124
- 108090000643 Vasopressin Receptors Proteins 0.000 claims description 124
- 150000001875 compounds Chemical class 0.000 claims description 107
- 102000001419 Melatonin receptor Human genes 0.000 claims description 100
- 108050009605 Melatonin receptor Proteins 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 92
- 230000000694 effects Effects 0.000 claims description 78
- 101000583209 Homo sapiens Prokineticin receptor 2 Proteins 0.000 claims description 68
- 102100030363 Prokineticin receptor 2 Human genes 0.000 claims description 68
- 239000005557 antagonist Substances 0.000 claims description 45
- 241000124008 Mammalia Species 0.000 claims description 30
- 102000005962 receptors Human genes 0.000 claims description 24
- 108020003175 receptors Proteins 0.000 claims description 24
- 239000000556 agonist Substances 0.000 claims description 23
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 20
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 20
- 208000024891 symptom Diseases 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000002060 circadian Effects 0.000 claims description 16
- 208000019116 sleep disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 14
- 208000000094 Chronic Pain Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 206010034960 Photophobia Diseases 0.000 claims description 10
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 208000005298 acute pain Diseases 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 208000005017 glioblastoma Diseases 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 239000002464 receptor antagonist Substances 0.000 claims description 10
- 229940044551 receptor antagonist Drugs 0.000 claims description 10
- 230000021907 regulation of circadian rhythm Effects 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 8
- 230000009395 genetic defect Effects 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 230000003340 mental effect Effects 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229940090046 jet injector Drugs 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 229940090048 pen injector Drugs 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- MJEREOGWNZGKRN-UHFFFAOYSA-N 1-(4-aminophenyl)-8-[4-(4-fluorophenyl)-4-oxobutyl]-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(N)=CC=C1N1C2(CCN(CCCC(=O)C=3C=CC(F)=CC=3)CC2)C(=O)NC1 MJEREOGWNZGKRN-UHFFFAOYSA-N 0.000 claims description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 230000027288 circadian rhythm Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 239000003885 eye ointment Substances 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000011653 vitamin D2 Substances 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- 235000001892 vitamin D2 Nutrition 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 206010012209 Delayed sleep phase Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021121456A JP2021169524A (ja) | 2016-04-06 | 2021-07-26 | プロキネチシン２アゴニストおよびアンタゴニストを使用する概日および日周リズムの障害を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319009P | 2016-04-06 | 2016-04-06 | |
| US62/319,009 | 2016-04-06 | ||
| PCT/US2017/026387 WO2017177026A1 (en) | 2016-04-06 | 2017-04-06 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121456A Division JP2021169524A (ja) | 2016-04-06 | 2021-07-26 | プロキネチシン２アゴニストおよびアンタゴニストを使用する概日および日周リズムの障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513738A JP2019513738A (ja) | 2019-05-30 |
| JP2019513738A5 true JP2019513738A5 (https=) | 2020-05-14 |
| JP7212930B2 JP7212930B2 (ja) | 2023-01-26 |
Family
ID=60001495
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552675A Active JP7212930B2 (ja) | 2016-04-06 | 2017-04-06 | プロキネチシン２アゴニストおよびアンタゴニストを使用する概日および日周リズムの障害を処置するための組成物および方法 |
| JP2021121456A Pending JP2021169524A (ja) | 2016-04-06 | 2021-07-26 | プロキネチシン２アゴニストおよびアンタゴニストを使用する概日および日周リズムの障害を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021121456A Pending JP2021169524A (ja) | 2016-04-06 | 2021-07-26 | プロキネチシン２アゴニストおよびアンタゴニストを使用する概日および日周リズムの障害を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10780095B2 (https=) |
| EP (1) | EP3439652A4 (https=) |
| JP (2) | JP7212930B2 (https=) |
| KR (1) | KR102461227B1 (https=) |
| CN (1) | CN109069477A (https=) |
| AU (1) | AU2017248277B2 (https=) |
| CA (1) | CA3019662A1 (https=) |
| WO (1) | WO2017177026A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021164770A1 (en) * | 2020-02-21 | 2021-08-26 | Peking University | Agents and methods for adjusting sleep |
| CN121154344A (zh) * | 2025-09-04 | 2025-12-19 | 中国人民解放军联勤保障部队第九二三医院 | 一种骨科患者皮肤牵引护理方法与系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575658A4 (en) * | 2002-04-15 | 2007-07-11 | Univ California | INVESTIGATION AND THERAPY PROCEDURE FOR THE TREATMENT OF DISORDERS OF THE CIRCADIAN RHYTHM |
| US20060172935A1 (en) * | 2005-01-31 | 2006-08-03 | Qun-Yong Zhou | Screening and therapeutic methods for treating circadian rhythm disorders |
| AU2006322067A1 (en) | 2005-12-06 | 2007-06-14 | Merck Sharp & Dohme Corp. | Morpholine carboxamide prokineticin receptor antagonists |
| CA2635845A1 (en) * | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 2 receptor antagonists |
| JP2011502154A (ja) | 2007-10-30 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。 |
| WO2010077976A2 (en) | 2008-12-17 | 2010-07-08 | The Regents Of The University Of California | Prokineticin receptor antagonists and uses thereof |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
-
2017
- 2017-04-06 CA CA3019662A patent/CA3019662A1/en active Pending
- 2017-04-06 US US16/090,044 patent/US10780095B2/en active Active
- 2017-04-06 AU AU2017248277A patent/AU2017248277B2/en active Active
- 2017-04-06 WO PCT/US2017/026387 patent/WO2017177026A1/en not_active Ceased
- 2017-04-06 JP JP2018552675A patent/JP7212930B2/ja active Active
- 2017-04-06 KR KR1020187032118A patent/KR102461227B1/ko active Active
- 2017-04-06 EP EP17779838.6A patent/EP3439652A4/en active Pending
- 2017-04-06 CN CN201780022483.7A patent/CN109069477A/zh active Pending
-
2021
- 2021-07-26 JP JP2021121456A patent/JP2021169524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential | |
| Pribish et al. | A review of nonanesthetic uses of ketamine | |
| Lerner et al. | Neuropsychiatric toxicity associated with cytokine therapies | |
| JP2015187125A5 (https=) | ||
| JP2012144512A (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
| JP2017533276A5 (https=) | ||
| RU2013140403A (ru) | Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа | |
| Alford et al. | Treatment of generalized convulsive status epilepticus in pediatric patients | |
| US11897875B2 (en) | Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders | |
| JP2013040195A5 (https=) | ||
| JP2019513738A5 (https=) | ||
| WO2025024637A1 (en) | Compositions for limiting sympathomimetic effects of psychedelic therapeutics | |
| KR20100132489A (ko) | 난소암을 치료하기 위하여 파클리탁셀을 포함하는 조합 | |
| JP2017524721A5 (https=) | ||
| CN105287519A (zh) | 一种预防术后谵妄的药物组合物 | |
| JP2012505830A5 (https=) | ||
| Keppel Hesselink | Bimoclomol and arimoclomol: HSP-co-inducers for the treatment of protein misfolding disorders, neuropathy and neuropathic pain | |
| Pisani et al. | Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. | |
| EP4308150A1 (en) | Improved methods of treating diseases resulting from a maladapted stress response | |
| JP2023505303A5 (https=) | ||
| Tesoro et al. | Pharmacological management of seizures and status epilepticus in critically ill patients | |
| Lončar-Stojiljković | Effects of esmolol infusion on cardiovascular parameters and quality of general anaesthesia in younger and older patients | |
| WO2023230303A1 (en) | Treatment of cognitive decline related to anesthesia and sedation | |
| RU2018144248A (ru) | Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта | |
| CN115887663A (zh) | 一种抗肿瘤的联合用药组合物 |